Jeffrey Velotta, MD, FACS
Clinical Associate Professor, Cardiothoracic Surgery
Bio
Dr. Jeffrey Velotta, MD, FACS is Clinical Associate Professor in the Department of Cardiothoracic Surgery, Stanford University School of Medicine, an adjunct Clinical Professor in the Department of Clinical Sciences at the Kaiser Permanente Bernard J. Tyson School of Medicine. Dr. Velotta received his MD from the George Washington University School of Medicine. He then went on to finish general surgery residency at UCLA along with a postdoctoral research fellowship in cardiothoracic surgery at Stanford University and completed his cardiothoracic surgery fellowship at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Velotta’s clinical and research interests involve improving equitable access to lung cancer screening, mesothelioma advancements, and innovative techniques for lung and esophageal cancer surgery.
Clinical Focus
- Thoracic and Cardiac Surgery
Professional Education
-
Board Certification: American Board of Thoracic Surgery, Thoracic and Cardiac Surgery (2015)
-
Residency: Brigham and Women's Thoracic Surgery Residency (2014) MA
-
Board Certification: American Board of Surgery, General Surgery (2013)
-
Residency: UCLA General Surgery Residency (2012) CA
-
Postdoctoral Research Fellowship, Stanford University School of Medicine, Cardiothoracic Surgery Transplantation (2009)
-
Medical Education: George Washington University School of Medicine and Health Sciences (2005) DC
All Publications
-
Misinformation and Overestimation of Computed Tomography Lung Cancer Screening Harms-Methodology Matters: A Joint Statement from The Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology.
The Annals of thoracic surgery
2027
View details for DOI 10.1016/j.athoracsur.2025.11.005
View details for PubMedID 41556861
-
Diaphragmatic Reconstruction with Strattice™ Biologic Mesh After Thoracic Oncologic Resection: A 10-Year Single-Center Retrospective Cohort Study
LIFE-BASEL
2026; 16 (10)
View details for DOI 10.3390/life16101597
View details for Web of Science ID 001914720600001
-
The Society of Thoracic Surgeons (2026) Expert Consensus Document on Management of Esophageal Perforation.
The Annals of thoracic surgery
2026
Abstract
BACKGROUND: Esophageal perforation is an uncommon but life-threatening condition that occurs spontaneously or as an iatrogenic injury following endoscopic intervention. The aim of this document was to provide a multi-disciplinary consensus on the diagnosis, treatment and follow-up for patients with suspected esophageal perforation.METHODS: A multidisciplinary panel from the Society of Thoracic Surgeons (STS) convened to develop consensus recommendations for the diagnosis and management of esophageal perforation. Evidence was identified through systematic searches of PubMed and Embase (2010-2024) using the the Population-Intervention-Comparator-Outcome (PICO) framework, and statements were finalized through a modified Delphi process requiring greater than 75% agreement among experts.RESULTS: Ten distinct recommendation statements were developed based on available literature. The statements all achieved greater than 75% consensus from all authors. The recommendations endorse the use of CT esophagram over fluoroscopic esophagram for diagnosis and the option of omitting imaging altogether in the event of spontaneous pneumomediastinum. There is a paucity of randomized control trials comparing endoscopic approaches for therapeutic management. However, current literature supports an array of endoscopic approaches based on technical aspects of the perforation and individual experience and skill.CONCLUSIONS: Early diagnosis with CT esophagram and individualized management emphasizing endoscopic approaches such as stenting or vacuum therapy optimize outcomes in esophageal perforation. Multidisciplinary, patient tailored decision making guided by available evidence and expert consensus remains essential given the limited high quality data.
View details for DOI 10.1016/j.athoracsur.2026.08.015
View details for PubMedID 42753881
-
An interview-based study of Asian American non-smoker lung cancer in the United States.
Chinese clinical oncology
2026; 15 (4): 64
View details for DOI 10.21037/cco-2026-1-0032
View details for PubMedID 42713693
-
Personal and Family History of Cancer and Primary Lung Cancer Prevalence Among Never Smoking Disaggregated Asian American Women.
Cancers
2026; 18 (12)
Abstract
Despite a decline in lung cancer in the U.S., lung cancer among never-smoking Asian American (AsA) women is rising, and subgroup aggregation obscures heterogeneity. We compared primary lung cancer prevalence across disaggregated AsA subgroups and examined factors associated with prevalence such as personal- and family-cancer histories versus Non-Hispanic Whites (NHWs).This cross-sectional study analyzed electronic health records of AsA women (≥18) in a large Northern California health system (2010-2022). Lung cancer cases were obtained from the hospital registry and categorized by smoking status and self-reported ethnicity. Adjusted prevalence ratios (aPRs) were estimated using targeted maximum likelihood estimation, accounting for sociodemographic, smoking, and clinical covariates.Among 1,843,119 women, 8651 had primary lung cancer; 2429 were never-smokers. In AsA never-smokers, aPRs and 95% confidence intervals versus age-matched NHW were: Chinese (3.36, [3.20-3.53]), Filipino (2.68, [2.55-2.82]), Vietnamese (2.07, [1.96-2.18]), Japanese (1.99, [1.89-2.10]), Korean (1.90, [1.80-2.00]), and Other Asian (0.35, [0.33-0.37]). Personal cancer-history reflected an increase in prevalence among Korean patients (2.91, [2.76-3.06]) while family cancer-history demonstrated increased prevalence among Chinese patients (1.51, [1.42-1.60]). Among women with uterine cancer, Chinese patients had higher lung-cancer prevalence than NHW (1.91, [1.58-2.31]).Never-smoking disaggregated AsA women show heterogeneous lung cancer prevalence, with higher prevalence in Korean women with personal cancer-history and in Chinese women with family cancer-history compared with NHW, supporting history-informed and ethnic-specific lung cancer screenings.
View details for DOI 10.3390/cancers18121862
View details for PubMedID 42352397
-
The Society of Thoracic Surgeons (2025) Expert Consensus Document on Interventions for Screen-Detected Lung Nodules.
The Annals of thoracic surgery
2026
Abstract
Computed tomographic (CT) lung cancer screening (LCS) reduces lung cancer-specific mortality and improves survival. We reviewed contemporary literature to develop consensus recommendations on perioperative quality standards for LCS programs to optimize outcomes.The Society of Thoracic Surgeons (STS) Task Force on Lung Cancer Screening and STS Workforce on Evidence Based Surgery convened a multidisciplinary panel of thoracic surgeons, radiation oncologists, and interventional pulmonologists. A comprehensive literature review was conducted using the Population-Intervention-Comparisons-Outcome framework. Consensus statements were developed through a modified Delphi process addressing: 1) preoperative biopsy and diagnostic surgical procedures, 2) acceptable rates of complications from diagnostic and therapeutic procedures, and 3) timing of intervention following a suspicious LCS finding and the role of the multidisciplinary team in patient management. Consensus required ≥75% agreement.Twenty-three consensus statements were developed after three Delphi rounds; 20 achieved consensus in the first round. Surgery without tissue diagnosis was acceptable for carefully selected patients, favoring minimally invasive, parenchymal-sparing approaches. Pneumonectomy without diagnosis was unanimously rejected. Programs should track benign resection rates. Acceptable complication benchmarks included pneumothorax <5%, hemoptysis <2%, and mortality <1% for bronchoscopic biopsy; and surgical morbidity <10%, 30-day mortality <1%, per STS database standards. Definitive resection should occur within 12 weeks of the inciting imaging study. Multidisciplinary teams should include thoracic surgery, oncology, pulmonology, and radiology. Preoperative pulmonary rehabilitation and smoking cessation were emphasized.This STS consensus defines perioperative quality standards for CT LCS programs, supporting shared decision-making, multidisciplinary care, and quality improvement.
View details for DOI 10.1016/j.athoracsur.2026.01.004
View details for PubMedID 41633462
-
Misinformation and Overestimation of Computed Tomography Lung Cancer Screening Harms-Methodology Matters: A Joint Statement from The Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology.
International journal of radiation oncology, biology, physics
2026
View details for DOI 10.1016/j.ijrobp.2025.12.030
View details for PubMedID 41556863
-
Misinformation and Overestimation of Computed Tomography Lung Cancer Screening Harms-Methodology Matters: A Joint Statement from The Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology.
Journal of the American College of Radiology : JACR
2025
View details for DOI 10.1016/j.jacr.2025.12.023
View details for PubMedID 41556871
-
Vaping nicotine is associated with increased medically-attended COVID-19 in women of reproductive age in an integrated health system.
Journal of thoracic disease
2025; 17 (11): 10023-10035
Abstract
Vaping in adolescents and young adults is increasingly common and has been shown to cause deleterious effects. Little is known about the effects of vaping on risk of coronavirus disease 2019 (COVID-19) among women of reproductive age. This study evaluated whether vaping nicotine and/or cannabis during the year before pregnancy was associated with medically-attended COVID-19 episodes.This large multicenter cross-sectional retrospective study evaluated women universally screened for vaping during the year before pregnancy as part of standard prenatal care from 9/1/2021 to 3/31/2023. Data came from the electronic health record and included nicotine and/or cannabis vaping during the year before pregnancy (exposure), medically-attended COVID-19 episode during the year before pregnancy (outcome), current and 5-year-history of tobacco smoking status, age, race/ethnicity, neighborhood deprivation index, body mass index, parity and Elixhauser Comorbidity Score. Associations between vaping and medically-attended COVID-19 episodes were estimated using Targeted Maximum Likelihood Estimation (TMLE) adjusting for covariates. Sensitivity analyses were performed after excluding women who had a history of current/former tobacco smoking.The sample of 71,508 reproductive-aged women had a mean (standard deviation) age of 31.7 (5.2) years and 67.6% were non-White. Overall, 2,347 (3.3%) reported vaping nicotine and 3,505 (4.9%) reported vaping cannabis during the year before pregnancy (2.47% vaped nicotine only, 4.10% vaped cannabis only, and 0.81% vaped both). The prevalence of having a medically-attended COVID-19 episode was higher among those who vaped vs. did not vape nicotine (16.9% vs. 14.1%) and among those who vaped nicotine only (17.0%) or nicotine and cannabis (16.8%) vs. neither (14.1%). In the adjusted analyses, the prevalence of a medically-attended COVID-19 episode was greater among those who vaped nicotine (vs. no nicotine vaping) [adjusted prevalence ratio (aPR) =1.33, 95% confidence interval (CI): 1.16-1.53] and among those who vaped nicotine only (aPR =1.32 (05% CI: 1.14-1.52) or both nicotine and cannabis (aPR =1.40, 95% CI: 1.28-1.54) vs. those who did not vape. Vaping cannabis was not associated with medically-attended COVID-19 episode risk.Vaping nicotine only or in combination with cannabis was positively associated with medically-attended COVID-19 episodes among women during the year prior to pregnancy. Future research is needed to understand the mechanisms underlying this association.
View details for DOI 10.21037/jtd-2025-580
View details for PubMedID 41376994
View details for PubMedCentralID PMC12688581
-
Lung Cancer Screening Disparities in Asian American Subgroups in a Large Integrated Health System.
The American surgeon
2025: 31348251353073
Abstract
BackgroundLung cancer is the leading cause of cancer-related deaths worldwide in Asian Americans (AsA), yet AsA lung cancer screening (LCS) rates are unknown. We examined LCS rates in AsA within Kaiser Permanente Northern California (KPNC), a large integrated healthcare system where LCS is a member benefit. The California LCS rate is 0.7%.MethodsThis cohort study analyzed KPNC 2015-2022 electronic health records. Lung cancer screening rates were compared among AsA subgroups, controlling for sociodemographics, considering both more restrictive 2013 (n = 2,273) and more inclusive 2021 (n = 5,823) United States Preventive Services Task Force (USPSTF) LCS guidelines, which differ by age range and years post-smoking cessation.ResultsOverall KPNC LCS rates for eligible AsA patients were 4.3% and 2.7% using USPSTF 2013 and 2021 guidelines, respectively. Lung cancer screening rates varied by AsA subgroup. Under 2021 guidelines, Chinese (4.0%) were screened more than Korean (3.57%), Southeast Asian (3.52%), Japanese (3.19%), Asian (Other) (2.28%), Pacific Islander (1.91%), and Filipino (1.55%). Under 2013 guidelines, Southeast Asian (6.54%) were screened more than Chinese (6.51%), Japanese (5.36%), Asian (Other) (3.95%), and Filipino (1.93%).DiscussionThis is the first study to demonstrate significant heterogeneity in LCS rates for disaggregated AsA subgroups. Kaiser Permanente Northern California LCS rates were 4× California rates. When payment alone is not a care barrier, systemic and culturally sensitive interventions are necessary to increase overall LCS screening rates and address population-specific disparities.
View details for DOI 10.1177/00031348251353073
View details for PubMedID 40551614
-
Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
Journal of the National Cancer Institute
2024
Abstract
Lung cancer is a leading cause of cancer mortality for most ethnic groups of Asian American females, including Chinese, Korean, Japanese, and Vietnamese Americans, a striking pattern given the exceedingly low prevalence of smoking among Asian American females in the general population. Recent research demonstrates that among Asian American females diagnosed with lung cancer, the vast majority of patients have never smoked, as high as > 80% among Chinese and Asian Indian American females. Despite declining rates in lung cancer overall in the United States, rates among Asian American females who have never smoked appear to be increasing. This Commentary articulates extant knowledge, based on studies in Asia, of a range of risk factors such as a family history of lung cancer, history of lung diseases including tuberculosis and chronic obstructive pulmonary diseases, exposure to cooking fumes and second-hand smoke, and various putative risk factors. Unique mutational profiles at the tumor level, including higher prevalence of EGFR mutations among Asian populations, highlight the importance of tumor genomic testing of newly-diagnosed patients. Additional research is essential, given the high burden of disease among Asian American females who have never smoked, and limited knowledge regarding contributing risk factors specific to Asian American females, as the risk factors identified in Asians living in Asia may not apply.
View details for DOI 10.1093/jnci/djae299
View details for PubMedID 39565906
-
Representativeness of Patients With Lung Cancer in an Integrated Health Care Delivery System.
The Permanente journal
2024: 1-10
Abstract
Observational research is important for understanding the real-world benefits of advancements in lung cancer care. Integrated health care systems, such as Kaiser Permanente Northern California, have extensive electronic health records suitable for such research, but the generalizability of their populations is often questioned.Leveraging data from the California Cancer Registry, the authors compared distributions of demographic and clinical characteristics, in addition to neighborhood and environmental conditions, between patients diagnosed with lung cancer from 2015 through 2019 at Kaiser Permanente Northern California, National Cancer Institute-designated cancer centers (NCICCs), and all other non-NCICC hospitals within the same catchment area.Of 20,178 included patients, 30% were from Kaiser Permanente Northern California, 8% from NCICCs, and 62% from other non-NCICC hospitals. Compared to NCICC patients, Kaiser Permanente Northern California patients were more similar to other non-NCICC patients on most characteristics. Compared to other non-NCICC patients, Kaiser Permanente Northern California patients were slightly older, more likely to be female, and less likely to be Hispanic or Asian/Pacific Islander and to reside in lower socioeconomic status (SES) neighborhoods. In contrast, NCICC patients were younger, less likely to be female or from non-Asian/Pacific Islander minoritized racial groups, and more likely to present with early-stage disease and adenocarcinoma and to reside in neighborhoods with higher SES and lower air pollution than Kaiser Permanente Northern California or other non-NCICC patients.Patients from Kaiser Permanente Northern California, compared to NCICCs, are more broadly representative of the underlying patient population with lung cancer.Research using electronic health record data from integrated health care systems can contribute generalizable real-world evidence to benchmark and improve lung cancer care.
View details for DOI 10.7812/TPP/24.028
View details for PubMedID 38980792
-
Paeoniflorin loaded liposomes modified with glycyrrhetinic acid for liver-targeting: preparation, characterization, and pharmacokinetic study
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
2024; 29 (3): 176-186
Abstract
To enhance the retention times and therapeutic efficacy of paeoniflorin (PF), a liver-targeted drug delivery system has been developed using glycyrrhetinic acid (GA) as a ligand.The development and optimization of GA-modified PF liposomes (GPLs) have shown promising potential for targeted delivery to the liver, opening up new possibilities for liver disease treatment.This study aimed to identify the best prescriptions using single-factor experiments and response surface methodology. The formulation morphology was determined using transmission electron microscopy. Tissue distribution was observed through in vivo imaging, and pharmacokinetic studies were conducted.The results indicated that GPLs, prepared using the thin film dispersion method and response surface optimization, exhibited well-dispersed and uniformly sized particles. The in vitro release rate of GPLs was slower compared to PF monomers, suggesting a sustained release effect. The liver-targeting ability of GA resulted in stronger fluorescence signals in the liver for targeted liposomes compared to non-targeted liposomes. Furthermore, pharmacokinetic studies demonstrated that GPLs significantly prolonged the residence time of PF in the bloodstream, thereby contributing to prolonged efficacy.These findings suggest that GPLs are more effective than PF monomers in terms of controlling drug release and delivering drugs to specific targets, highlighting the potential of PF as a liver-protective drug.
View details for DOI 10.1080/10837450.2024.2319738
View details for Web of Science ID 001178431900001
View details for PubMedID 38376879
-
Representativeness of patients with lung cancer in an integrated health care delivery system
LIPPINCOTT WILLIAMS & WILKINS. 2023
View details for Web of Science ID 001053772001491
-
Representativeness of patients with lung cancer in an integrated health care delivery system.
LIPPINCOTT WILLIAMS & WILKINS. 2023: e13600
View details for DOI 10.1200/JCO.2023.41.16_suppl.e13600
View details for Web of Science ID 001555536600008
-
Interleukin-16 deficiency suppresses the development of chronic rejection in murine cardiac transplantation model
JOURNAL OF HEART AND LUNG TRANSPLANTATION
2011; 30 (12): 1409-1417
Abstract
IL-16 promotes the recruitment of various cells expressing CD4, a receptor for IL-16. The precise role of IL-16 in transplant rejection remains unknown; therefore, the present study investigated the contribution of IL-16 to the development of chronic rejection in heart transplants.C-H-2(bm12)KhEg (H-2(bm12)) donor hearts were transplanted into (1) IL-16-deficient (IL-16(-/-)) C57BL/6J or (b) wild type (WT) control recipients (MHC class II mismatch). Grafts were harvested at 52 days, parenchymal rejection was assessed by the ISHLT grading system, and CAV was examined morphometrically. Graft infiltrating cells were detected 10 and 52 days after transplantation. Intragraft cytokine and chemokine profiles were assessed. To confirm the role of IL-16 in CAV development, C-H-2(bm12)KhEg (H-2(bm12)) donor hearts were transplanted into C57BL/6J WT recipients treated with (1) anti-IL-16-neutralization monoclonal antibody or (b) control immunoglobulin G. Grafts were harvested at 52 days, and CAV was quantified morphometrically. Graft-infiltrating cells were examined histologically.Parenchymal rejection and CAV was significantly attenuated in donor hearts transplanted into IL-16(-/-) recipient mice compared with WT controls. Donor hearts transplanted into IL-16(-/-) recipients had a significant reduction in coronary artery luminal occlusion, intima-to-media ratio, and percentage of diseased vessels. CAV was associated with decreased donor organ inflammation, as well as donor organ cytokine (IL-1β and IL-6) and chemokine (MCP-1 and KC) protein expression. Intimal proliferation and inflammatory cell infiltration were significantly reduced in hearts transplanted into recipients treated with an IL-16-neutralization antibody.IL-16-deficiency reduced graft inflammatory cell recruitment, and allograft inflammatory cytokine and chemokine production. Therefore, IL-16 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection.
View details for DOI 10.1016/j.healun.2011.08.017
View details for Web of Science ID 000297385400016
View details for PubMedID 22055099
-
Interleukin-17 Accelerates Allograft Rejection by Suppressing Regulatory T Cell Expansion
Annual Meeting of the American-Heart-Association
LIPPINCOTT WILLIAMS & WILKINS. 2011: S187–S196
Abstract
Interleukin-17 (IL-17), which is predominantly produced by T helper 17 cells distinct from T helper 1 or T helper 2 cells, participates in the pathogenesis of infectious, autoimmune, and allergic disorders. However, the precise role in allograft rejection remains uncertain. In the present study, we investigated the role of IL-17 in acute allograft rejection using IL-17-deficient mice.Donor hearts from FVB mice were heterotopically transplanted into either C57BL/6J-IL-17-deficient (IL-17(-/-)) or -wild-type mice. Allograft survival was significantly prolonged in IL-17(-/-) recipient mice due to reduced local inflammation accompanied by decreased inflammatory cell recruitment and cytokine/chemokine expression. IL-17(-/-) recipient mice exhibited decreased IL-6 production and reciprocally enhanced regulatory T cell expansion, suggesting a contribution of regulatory T cells to prolonged allograft survival. Indeed, allografts transplanted into anti-CD25 mAb-treated IL-17(-/-) recipient mice (regulatory T cell-depleted) developed acute rejection similar to wild-type recipient mice. Surprisingly, we found that gamma delta T cells rather than CD4(+) and CD8(+) T cells were key IL-17 producers in the allografts. In support, equivalent allograft rejection was observed in Rag-2(-/-) recipient mice engrafted with either wild-type or IL-17(-/-) CD4(+) and CD8(+) T cells. Finally, hearts transplanted into gamma delta T cell-deficient mice resulted in decreased allograft rejection compared with wild-type controls.During heart transplantation, (1) IL-17 is crucial for acceleration of acute rejection; (2) IL-17-deficiency enhances regulatory T cell expansion; and (3) gamma delta T cells rather than CD4(+) and CD8(+) T cells are a potential source of IL-17. IL-17 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection.
View details for DOI 10.1161/CIRCULATIONAHA.110.014852
View details for Web of Science ID 000294782800025
View details for PubMedID 21911812
-
Prevention of transplant coronary artery disease by prenylation inhibitors
JOURNAL OF HEART AND LUNG TRANSPLANTATION
2011; 30 (7): 761-769
Abstract
In this study we systematically dissect the prenylation pathway to better define the mechanism behind statin inhibition in chronic allograft rejection in heart transplants, or transplant coronary artery disease (TCAD).Utilizing a murine heterotopic heart transplant model, animals received daily treatments of either statin or selective isoprenoid blockade inhibitors to block the four major downstream branches of the mevalonate pathway. TCAD was assessed by morphometric analysis at Day 52. Graft-infiltrating cells, cytokine production, smooth muscle cell proliferation and migration and endothelial cell MHC II expression were detected on Day 7.Atorvastatin and two prenylation inhibitors, NE-10790 and manumycin A, significantly reduced TCAD lesions compared with untreated animals. Perillyl alcohol treatment resulted in a trend toward decreased luminal narrowing. Finally, zaragozic acid (cholesterol blockade only) did not alter TCAD severity. Statins and prenylation inhibitors reduced inflammatory cell allograft recruitment, but did not always correlate with TCAD reduction. Cytokine production was decreased in recipient spleens in all treatment groups. Both in vitro and in vivo IFN-γ-stimulated MHC II expression was decreased in a dose-dependent manner in the atorvastatin, perillyl alcohol and NE-10790 groups. In vitro smooth muscle cell proliferation was decreased in all treatment groups. Finally, in vitro smooth muscle cell migration was decreased in the atorvastatin, NE-10790 and manumycin A groups only.FPT and GGPT-2 (inhibition) are the key enzymes in the HGM-CoA reductase pathway and most influential in TCAD prevention. TCAD reduction is most closely related to smooth muscle cell migration, but not its anti-inflammatory properties.
View details for DOI 10.1016/j.healun.2011.01.720
View details for Web of Science ID 000291898800004
View details for PubMedID 21458297
-
alpha B-Crystallin Improves Murine Cardiac Function and Attenuates Apoptosis in Human Endothelial Cells Exposed to Ischemia-Reperfusion
ANNALS OF THORACIC SURGERY
2011; 91 (6): 1907-1913
Abstract
This study investigates the protective effect of exogenous αB-crystallin (CryAB) on myocardial function after ischemia-reperfusion injury.Mice underwent temporary left anterior descending artery occlusion for 30 minutes. Either CryAB (50 μg) or phosphate-buffered saline (100 μL [n=6, each group]) were injected in the intramyocardial medial and lateral perinfarct zone 15 minutes before reperfusion. Intraperitoneal injections were administered every other day. Left ventricular ejection fraction was evaluated on postoperative day 40 with magnetic resonance imaging. To investigate the effect of CryAB on apoptosis after hypoxia/reoxygenation in vitro, murine atrial cardiomyocytes (HL-1 cells) or human microvascular endothelial cells (HMEC-1) were incubated with either 50 μg CryAB (500 μg /10 mL) or phosphate-buffered saline in a hypoxia chamber for 6, 12, and 24 hours, followed by 30 minutes of reoxygenation at room air. Apoptosis was then assessed by western blot (Bcl-2, free bax, cleaved caspases-3, 9, PARP) and enzyme-linked immunosorbent assay analyses (cytoplasmic histone-associated DNA fragments and caspase-3 activity).On postoperative day 40, CryAB-treated mice had a 1.8-fold increase in left ventricular ejection fraction versus control mice (27%±6% versus 15%±4% SD, p<0.005). In vitro, (1) the HL-1 cells showed no significant difference in apoptotic protein expression, cytoplasmic histone-associated DNA fragments, or caspase-3 activity; (2) the HMEC-1 cells had increased but not significant apoptotic protein expression with, however, a significant decrease in cytoplasmic histone-associated DNA fragments (1.5-fold, p<0.01) and caspase-3 activity (2.7-fold, p<0.005).Exogenous CryAB administration significantly improves cardiac function after ischemia-reperfusion injury, in vivo. The protective anti-apoptotic affects of CryAB may target the endothelial cell.
View details for DOI 10.1016/j.athoracsur.2011.02.072
View details for Web of Science ID 000291019400043
View details for PubMedID 21619989
-
Interleukin-17 Accelerates Allograft Rejection by Suppressing Regulatory T Cell Expansion
LIPPINCOTT WILLIAMS & WILKINS. 2010
View details for Web of Science ID 000208231603509
-
The role of recipient mast cells in acute and chronic cardiac allograft rejection in C57BL/6-KitW-sh/W-sh mice
JOURNAL OF HEART AND LUNG TRANSPLANTATION
2010; 29 (4): 401-409
Abstract
Mast cells are hypothesized to promote rejection and adverse remodeling in cardiac allografts. In contrast, it has been reported that mast cells may enhance cardiac allograft survival in rats. We used C57BL/6-Kit(W-sh/W-sh) mast cell-deficient and corresponding wild-type mice to investigate possible contributions of recipient mast cells to acute or chronic cardiac allograft rejection.FVB (H-2(q); acute rejection), or C-H-2(bm12)KhEg (H-2(bm12); chronic rejection) donor hearts were heterotopically transplanted into C57BL/6-Kit(W-sh/W-sh) (H-2(b)) or C57BL/6-Kit(+/+) (H-2(b)) mice. The degree of acute rejection was assessed at 5 days and chronic rejection, at 52 days.In the acute rejection model, donor heart vascular cell adhesion molecule-1 (VCAM-1) expression was significantly lower in C57BL/6-Kit(W-sh/W-sh) than in wild-type recipients; however, acute rejection scores, graft survival, inflammatory cells, or cytokine expression did not differ significantly. In the chronic rejection model, the number of mast cells/mm(2) of allograft tissue was significantly increased 52 days after transplantation in allografts transplanted into C57BL/6-Kit(+/+) but not C57BL/6-Kit(W-sh/W-sh) mice; however, no substantial differences were noted in graft coronary artery disease, graft inflammatory cells, or levels of graft tissue expression of cytokines or adhesion molecules.Cardiac allografts undergoing chronic rejection in wild-type C57BL/6-Kit(+/+) mice exhibit increased numbers of mast cells, but acute or chronic cardiac allograft rejection can develop in C57BL/6-Kit(W-sh/W-sh) mice even though these recipients virtually lack mast cells. These findings indicate that recipient mast cells are not required for acute or chronic cardiac allograft rejection in the models examined.
View details for DOI 10.1016/j.healun.2009.08.019
View details for Web of Science ID 000276915100003
View details for PubMedID 19818646
-
IL-17 Contributes to the Development of Chronic Rejection in a Murine Heart Transplant Model
JOURNAL OF CLINICAL IMMUNOLOGY
2010; 30 (2): 235-240
Abstract
Although interleukin-17 (IL-17) has been reported to participate in the pathogenesis of infectious, autoimmune and allergic disorders, the precise role in allograft rejection remains uncertain. This study illustrates that IL-17 contributes to the pathogenesis of chronic allograft rejection.Utilizing a murine heterotopic heart transplant model system, IL-17-deficient recipient mice had decreased allograft inflammatory cell recruitment, decreased IL-6, MCP-1, and KC production, and reduced graft coronary artery disease (GCAD). Intragraft gamma delta (gammadelta) T cells appear to be the predominant source of IL-17 production.Therefore, IL-17 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection.
View details for DOI 10.1007/s10875-009-9366-9
View details for Web of Science ID 000275798900007
View details for PubMedID 20130970
-
Exogenous aB-crystallin Improves Myocardial Function and Attenuates Apoptosis in Ischemia-Reperfusion Injury
82nd National Conference and Exhibitions and Scientific Sessions of the American-Heart-Association
LIPPINCOTT WILLIAMS & WILKINS. 2009: S998–S998
View details for Web of Science ID 000271831503397
-
Metformin as a Cardioprotective Agent in Heart Transplantation Decreases Ischemia-Reperfusion Injury and Chronic Rejection
LIPPINCOTT WILLIAMS & WILKINS. 2009: S796
View details for Web of Science ID 000271831502400
-
A Novel JAK3 Inhibitor, R348, Attenuates Chronic Airway Allograft Rejection
TRANSPLANTATION
2009; 87 (5): 653-659
Abstract
This study aimed at investigating the role of a novel JAK3 inhibitor, R348, in the prevention of chronic airway allograft rejection.The heterotopic rat trachea transplant model was used. Recipients were treated daily with R348 (10, 20, 40, 80 mg/kg) or rapamycin (0.75 or 3 mg/kg). Blood levels of R348 and of its active metabolite R333 were measured. Grafts were harvested after 28 days to analyze epithelial morphology, mononuclear infiltration, and luminal obliteration. Plasma levels of circulating donor strain-reactive IgG antibodies were quantified.R348 was well tolerated at up to 40 mg/kg, but was toxic at 80 mg/kg. Blood levels of R333 at 2 and 24 hr were consistently 10 to 15 times higher than those of R348. Airway luminal obliteration after 28 days was significantly inhibited by R348 at 40 mg/kg (20.6%+/-13.2%, P<0.05) and 80 mg/kg (15.7%+/-7.6%, P<0.05) and by rapamycin at 3 mg/kg (11.6%+/-6.7% P<0.001) versus untreated controls (100%). R348 is more than or equal to 40 mg/kg but neither dose of rapamycin preserved the physiologic epithelial coverage with its prominent goblet cells population (8.8+/-1.5 goblet cells/microm circumference in syngeneic grafts and 8.0+/-0.9 and 4.3+/-1.2 with R348 80 mg/kg and 40 mg/kg, respectively). Peritracheal graft mononuclear infiltration was most effectively suppressed by R348 is more than or equal to 40 mg/kg (P<0.05) and rapamycin 3 mg/kg (P<0.01). Donor strain-reactive IgG antibodies were significantly decreased by R348 is more than or equal to 40 mg/kg (P=0.05) and rapamycin 3 mg/kg (P<0.001). Animals treated with R348 is more than or equal to 40 mg/kg showed elevated alanine transferase (P<0.05), whereas hypercholesterolemia was only found in animals receiving rapamycin 3 mg/kg (P<0.05).R348 is an effective drug, and it is expected to be introduced into clinical transplant pharmacology soon.
View details for DOI 10.1097/TP.0b013e318196110f
View details for Web of Science ID 000264146100006
View details for PubMedID 19295308
-
Comparison of Transplantation of Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stem Cells in the Infarcted Heart
TRANSPLANTATION
2009; 87 (5): 642-652
View details for DOI 10.1097/TP.0b013e31819609d9
View details for Web of Science ID 000264146100005
-
Comparison of Transplantation of Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stem Cells in the Infarcted Heart
TRANSPLANTATION
2009; 87 (5): 642-652
Abstract
Mesenchymal stem cells hold promise for cardiovascular regenerative therapy. Derivation of these cells from the adipose tissue might be easier compared with bone marrow. However, the in vivo fate and function of adipose stromal cells (ASC) in the infarcted heart has never been compared directly to bone marrow-derived mesenchymal cells (MSC).ASC and MSC were isolated from transgenic FVB mice with a beta-actin promoter driving firefly luciferase and green fluorescent protein double fusion reporter gene, and they were characterized using flow cytometry, microscopy, bioluminescence imaging and luminometry. FVB mice (n=8 per group) underwent myocardial infarction followed by intramyocardial injection of 5x10(5) ASC, MSC, fibroblasts (Fibro, positive control), or saline (negative control). Cell survival was measured using bioluminescence imaging for 6 weeks and cardiac function was monitored by echocardiography and pressure-volume analysis. Ventricular morphology was assessed using histology.ASC and MSC were CD34(-), CD45(-), c-Kit(-), CD90(+), Sca-1(+), shared similar morphology and had a population doubling time of approximately 2 days. Cells expressed Fluc reporter genes in a number-dependent fashion as confirmed by luminometry. After cardiac transplantation, both cell types showed drastic donor cell death within 4 to 5 weeks. Furthermore, transplantation of either cell type was not capable of preserving ventricular function and dimensions, as confirmed by pressure-volume-loops and histology.This is the first study comparing the in vivo behavior of both cell types in the infarcted heart. ASC and MSC do not tolerate well in the cardiac environment, resulting in acute donor cell death and a subsequent loss of cardiac function similar to control groups.
View details for DOI 10.1097/TP.0b013e31819609d9
View details for PubMedID 19295307
-
R348, a novel JAK3 and Syk-inhibitor, attenuates obliterative airway disease (OAD).
BLACKWELL PUBLISHING. 2008: 229
View details for Web of Science ID 000255763200192
-
Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection
TRANSPLANTATION
2008; 85 (6): 885-892
Abstract
Janus kinase (JAK)3 is crucial for signal transduction downstream of various cytokine receptors in immune cells. This is the first report on the novel JAK3 inhibitor R348.(1) Detailed pharmacokinetic data were obtained in rats; (2) multiple in vitro enzyme inhibition assays were performed to characterize the drug; (3) prevention of acute rejection was investigated in animals treated with different doses of R348 or rapamycin for 5 days; and (4) cardiac allograft survival after a 10-day treatment period was studied for various regimens of R348, tacrolimus, or rapamycin; combination indices were calculated to evaluate drug interactions.(1) Plasma levels of R348's active metabolite R333 sustained high for 8 hr or more, depending on the dose. (2) In vitro enzyme assays showed potent inhibition of JAK3- and Syk-dependent pathways. (3) R348 40 mg/kg preserved graft function, significantly reduced graft infiltration, and decreased histologic ISHLT rejection scores on postoperative day 5. Results were similar to those of rapamycin 3 mg/kg. Likewise, both drugs significantly reduced the cellular Th1 and Th2 immune responses, as determined by enzyme-linked immunosorbent assays. Intragraft inflammatory cytokine upregulation was similarly suppressed by R348 and rapamycin. R348 10 mg/kg was subtherapeutic. (4) Allograft survival was similar for R348 20 and 40 mg/kg, which was comparable with therapeutically dosed tacrolimus or rapamycin. In combination regimens, R348 demonstrated highly beneficial synergistic interactions with tacrolimus.R348 is a promising novel JAK3/Syk-inhibitor with favorable pharmacokinetics and biological activity. It effectively diminishes acute cardiac allograft rejection and is suitable for combination regimens with tacrolimus.
View details for DOI 10.1097/TP.0b013e318166acc4
View details for Web of Science ID 000254592000017
View details for PubMedID 18360272
https://orcid.org/0000-0002-1405-8487